Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection-Reference-Cited by-同舟云学术

Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection

Published:2018-07-17 Issue:1 Volume:54 Page:78-86
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Suda Goki, ,Kurosaki Masayuki,Itakura Jun,Izumi Namiki,Uchida Yoshihito,Mochida Satoshi,Hasebe Chitomi,Abe Masami,Haga Hiroaki,Ueno Yoshiyuki,Masakane Ikuto,Abe Kazumichi,Takahashi Atsushi,Ohira Hiromasa,Furuya Ken,Baba Masaru,Yamamoto Yoshiya,Kobayashi Tomoe,Kawakami Atsuhiko,Kumagai Kenichi,Terasita Katsumi,Ohara Masatsugu,Kawagishi Naoki,Umemura Machiko,Nakai Masato,Sho Takuya,Natsuizaka Mitsuteru,Morikawa Kenichi,Ogawa Koji,Sakamoto Naoya

Funder

Japan Agency for Medical Research and Development

Japan Society for the Promotion of Science

Merck & Co

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/article/10.1007/s00535-018-1495-6/fulltext.html

Reference32 articles.

1. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.